Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized MSC Exosomes for COVID-19
NCT05787288Phase 1Unknown
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Jan 2023
- Primary completion
- Jan 2024
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of mesenchymal stem cell-derived extracellular vesicles in COVID-19 pneumonia (2 arms), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoints: Symptom remission time after atomizing medication at 3 months, Improvement of serum inflammatory markers at 3 months and 1 more. Status: unknown.
02
Drugs
mesenchymal stem cell-derived extracellular vesicles
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT05787288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05787288.